Latest News

Pharmaceutical Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Pharmaceutical Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Pharmaceutical Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

Features Biotech Report: Will Gene Therapy Go Mainstream?

Biotech Report: Will Gene Therapy Go Mainstream?

The products are safe. The science is rock-solid. Patients are champing at the bit. But as much as the industry may be lining up behind gene therapies, marketing and operational questions abound. Larry Dobrow reports on the current state of the gene therapy union

Pharmaceutical

MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Pharmaceutical Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Features Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

Features Headliner: Silk smooths Takeda myeloma shift

Headliner: Silk smooths Takeda myeloma shift

He didn't want to just invest in a winning horse—he wanted to help groom it

Pharmaceutical FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

Pharmaceutical The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.